GNH USA

Europe — EMA

Miglustat Bluefish

GNH USA supplies Miglustat Bluefish (Miglustat), a glucosylceramide synthase inhibitor for Niemann-Pick disease type C and Gaucher disease type 1.

Miglustat

Request sourcing

1
Pack/s

What is Miglustat?

Miglustat, the active ingredient in Miglustat Bluefish, is a glucosylceramide synthase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of Niemann-Pick disease type C and Gaucher disease type 1 in patients who meet clinical criteria.

GNH USA supplies Miglustat Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

What is Miglustat used for?

Miglustat is used as substrate reduction therapy for lysosomal storage disorders affecting glycosphingolipid metabolism.

Niemann-Pick disease type C: reduces accumulation of glycosphingolipids in the central nervous system, helping to stabilize neurological function. Gaucher disease type 1: lowers substrate buildup in macrophages, contributing to reduced organomegaly and improved hematologic parameters.

What are the side effects of Miglustat?

Miglustat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: watery stools occurring during treatment. - Nausea: feeling of stomach upset or urge to vomit. - Abdominal pain: discomfort or cramps in the stomach area. - Weight loss: unintended reduction in body weight.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas requiring medical attention. - Severe hypersensitivity: rash, swelling, or anaphylactic reactions. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress.

What precautions apply to Miglustat?

Before initiating therapy, clinicians should consider several safety measures.

Monitor liver function: obtain baseline tests and repeat periodically. Assess gastrointestinal tolerance: advise patients to report persistent diarrhea or vomiting. Evaluate neurological status: watch for tremor, ataxia, or worsening coordination. Review concomitant medications: avoid strong CYP3A4 inhibitors where possible. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

What does Miglustat interact with?

Miglustat can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase miglustat exposure. - Strong CYP2C9 inhibitors (e.g., fluconazole): can raise plasma concentrations. - High‑dose oral contraceptives: may have reduced effectiveness.

Moderate Interactions (Monitor Closely): - Digoxin: monitor serum levels for potential increase. - Warfarin: observe INR for possible alteration. - Antacids containing aluminum or magnesium: may affect absorption, separate dosing by at least 2 hours.

Frequently asked questions

What is Miglustat Bluefish used for?+
Miglustat Bluefish is prescribed as substrate reduction therapy for patients with Niemann‑Pick disease type C and Gaucher disease type 1. In these rare lysosomal storage disorders, the drug helps lower the buildup of glycosphingolipids, which can improve organ function and, in the case of Niemann‑Pick, may stabilize neurological symptoms.
How does Miglustat work?+
Miglustat blocks the enzyme glucosylceramide synthase, the first step in the synthesis of glycosphingolipids. By inhibiting this enzyme, the drug reduces the production of glucosylceramide and related lipids, decreasing their accumulation in cells that are affected by Niemann‑Pick disease type C and Gaucher disease type 1.
What is the usual dose of Miglustat Bluefish?+
The dosage of Miglustat Bluefish is individualized by the prescribing clinician based on the patient’s age, weight, disease severity, and renal function. Healthcare professionals determine the appropriate regimen and adjust it according to therapeutic response and tolerability.
Is Miglustat Bluefish safe in pregnancy or breastfeeding?+
Safety data for Miglustat during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and a healthcare provider should evaluate each case carefully.
How do I order Miglustat Bluefish from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.
How does Miglustat compare with the main alternative therapy?+
The primary alternative for Gaucher disease type 1 is enzyme replacement therapy (e.g., imiglucerase), which supplies the missing enzyme directly. Miglustat, by contrast, reduces the synthesis of the substrate that accumulates. While enzyme replacement targets the underlying deficiency, Miglustat offers an oral option that may be preferred for patients unable to receive infusions, though efficacy and side‑effect profiles differ.
What are the storage and handling requirements for Miglustat Bluefish?+
Miglustat Bluefish should be stored at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it out of direct sunlight. Do not refrigerate or freeze the tablets, as temperature extremes can affect stability.
How is Miglustat Bluefish administered?+
Miglustat Bluefish is taken orally, usually with a glass of water. It can be administered with or without food, but taking it with meals may help reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their clinician and not alter the regimen without medical advice.
What are the most serious risks to watch for while taking Miglustat Bluefish?+
Serious adverse events include pancreatitis, severe hypersensitivity reactions (such as rash, swelling, or anaphylaxis), and significant liver enzyme elevations indicating hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, jaundice, unexplained fever, or any signs of an allergic reaction.
Who should not use Miglustat Bluefish?+
Miglustat Bluefish is contraindicated in individuals with known hypersensitivity to miglustat or any of its excipients. It should also be avoided in patients with severe hepatic impairment and is generally not recommended for pregnant women unless the potential benefit outweighs the risk. Clinicians must assess each patient’s medical history before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Miglustat
Route
Oral Use
Manufacturer
Bluefish Pharmaceuticals Ab
Origin
EU

Related products

Miglustat 100 mg/1

Miglustat 100 mg/1

Miglustat · 100 mg

Miglustat
CAPSULE
CoTherix, Inc.
USA
Zavesca 100 mg

Zavesca 100 mg

Miglustat · 100 MG

Zavesca
CAPSULE
JANSSEN INC
CANADA
Sandoz Miglustat 100 mg

Sandoz Miglustat 100 mg

Miglustat · 100 MG

Sandoz Miglustat
CAPSULE
SANDOZ CANADA INCORPORATED
CANADA
Miglustat Accord

Miglustat Accord

Miglustat

Accord Healthcare Limited
EU